Treatment after myocardial infarction

Comprehensive Therapy

Volumn 33, Issue 1, 2007, Pages 39-47

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CLOPIDOGREL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FIBRIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; METOPROLOL; NICOTINIC ACID; NIFEDIPINE; NITRIC ACID DERIVATIVE; PERINDOPRIL; PLACEBO; PROPRANOLOL; RAMIPRIL; SULFONYLUREA DERIVATIVE; TIMOLOL; UNINDEXED DRUG; WARFARIN;

ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DOSE INCREASE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOW DRUG DOSE; PHYSICAL ACTIVITY;

AGED; DEFIBRILLATORS, IMPLANTABLE; DIABETES MELLITUS; DIET THERAPY; EXERCISE; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; OBESITY; SMOKING CESSATION;

EID: 36248979838     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12019-007-0002-4     Document Type: Article

References (59)

1. Hermanson B, Omenn GS, Kronmal RA, Gersh BJ. Beneficial sixyear outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS registry. N Engl J Med 1988;319:1365-9.
2. Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol 1996;77:864-6.
3. Smith Jr SC, Allen J, Blair SN, et al. ACC/AHA guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72.
4. 2003 Joint National Committee. The seventh report of the joint national committee on the detection, evaluation, and treatment of high blood pressure (JNC VII). JAMA 2003;289:2560-72.
5. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
6. Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol 2001;88:1298-300.
7. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers. Am J Cardiol 2002;89:1207-9.
8. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
9. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation. Endorsed by the Heart Rhythm Society. J Am Coll Cardiol 2005;46:1116-43.
10. American Diabetes Association. Treatment of hypertension of adults with diabetes. Diabetes Care 2003;26(suppl 1):580-2.
11. Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: The Framingham Study. Ann Intern Med 1991;115:687-93.
12. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211-8.
13. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) Trial. Ann Intern Med 1998;129:681-9.
14. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
16. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Eng J Med 2005;352:1425-35.
17. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dL treated with statins versus no lipid-lowering drug. Am J Cardiol 2002;89:67-9.
18. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
19. Gregoratos G, Leung G. Diabetes mellitus and cardiovascular disease in the elderly. In: Aronow WS, Fleg JL, editors. Cardiovascular disease in the elderly, third edition, revised and expanded, New York: Marcel Dekker; 2004. pp. 163-88.
20. Sukhija R, Aronow WS, Kakar P, et al. Relation of microalbuminuria and coronary artery disease in patients with and without diabetes mellitus. Am J Cardiol 2006;98:279-81.
21. Ravipati G, Aronow WS, Ahn C, et al. Association of hemoglobin A1c level with the severity of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 2006;97:968-9.
22. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33:119-24.
23. O'Keefe JH, Blackstone EH, Sergeant P, McCallister BD. The optimal mode of coronary revascularization for diabetics. Eur Heart J 1998;19:1696-703.
24. Aronow WS, Ahn C. Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. Am J Cardiol 2001;88:556-7.
25. Aronow WS. Exercise therapy for older persons with cardiovascular disease. Am J Geriatr Cardiol 2001;10:245-52.
26. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86.
27. Fiore LD, Ezekowitz MD, Brophy MT, et al. Combination Hemotherapy and Mortality Prevention (CHAMP) Study Group. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMPs study. Circulation 2002;105:557-63.
28. Aronow WS, Ahn C. Reduction of coronary events with aspirin in older patients with prior myocardial infarction treated with and without statins. Heart Disease 2002;4:159-61.
29. Smith Jr SC, Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001;38:1581-3.
30. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
31. Aronow WS, Frishman WH. Angina in the elderly. In: Aronow WS, Fleg J, editors. Cardiovascular disease in the elderly. third edition, revised and expanded. New York City: Marcel Dekker, Inc.; 2004. pp. 273-95.
32. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-95.
33. Gundersen T, Abrahamsen AM, Kjekshus J, et al. Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Circulation 1982;66:1179-84.
34. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982;247:1707-14.
35. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
36. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-21.
37. Yusuf S, Wittes J, Probstfield J. Evaluating effects of treatment subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers. Am J Cardiol 1990;60:220-2.
38. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
39. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
40. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362: 782-8.
41. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991;67:1295-7.
42. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92.
43. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases lateonset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991;83:52-60.
44. Aronow WS, Mercando AD, Epstein S, Kronzon I. Effect of quinidine or procainamide versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in elderly patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1990;66:423-8.
45. Julian DJ, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;1:1142-7.
46. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-74.
47. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-82.
48. Greene HL, for the CASCADE Investigators. The CASCADE study. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol 1993;72:70F-4F.
49. Herre J, Sauve M, Malone P, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989;13:442-9.
50. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1994;74:674-80.
51. Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%. Am J Cardiol 1994;74:267-70.
52. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
53. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
54. Goldenberg I, Moss AJ. Treatment of arrhythmias and use of implantable cardioverter-defibrillators to improve survival in elderly patients with cardiac disease. In: Aronow WS, editor. Clinics in geriatric medicine on heart failure, vol. 23. Philadelphia: Elsevier; 2007. pp. 205-19.
55. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
56. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-Up (HERS II). JAMA 2002;288:49-57.
57. Davis MM, Taubert K, Benin AL, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. J Am Coll Cardiol 2006;48:1498-502.
58. Laham CL, Singh M, Holmes Jr DR. Percutaneous coronary intervention in the elderly. In: Aronow WS, Fleg J, editors. Cardiovascular disease in the elderly. third edition, revised and expanded. New York City: Marcel Dekker, Inc.; 2004. pp. 389-404.
59. Stemmer EA, Aronow WS. Surgical management of coronary artery disease in the elderly. In: Aronow WS, Fleg J, editors. Cardiovascular disease in the elderly. third edition, revised and expanded. New York City: Marcel Dekker, Inc.; 2004. pp. 353-88.